Skip to main content
SpringerLink
Log in

Postmarketing study confirms safety of XIENCE V stent

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB.A New Era of Prospective Real-World Safety Evaluation: Primary Report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System Condition-of-Approval Post-Market Study). JACC: Cardiovascular Interventions 4: 1298-1309, No. 12, Dec 2012. Available from: URL: http://dx.doi.org/10.1016/j.jcin.2011.08.010

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postmarketing study confirms safety of XIENCE V stent. React. Wkly. 1384, 5 (2012). https://doi.org/10.2165/00128415-201213840-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00016

Keywords

Search

Navigation